| Classification |
B Cell Antigens |
T Cell Antigens |
Other
Antigens |
Genetic
Features |
| CD19 |
CD20 |
CD22 |
CD2 |
CD3 |
CD5 |
CD7 |
CD4 / CD8 |
| B
Cell Lymphomas |
| Precursor B-lymphoblastic
leukemia/lymphoma (B-LBL) |
+ |
-/+ |
+ |
- |
- |
- |
- |
- |
CD10+/-; CD13
ps; CD33 ps; CD34+/-; HLADR+; sIg-; cytoplasmic mu -/+; TdT+ |
Ig HC
rg; Ig LC rg-ps; TCR rg (mn) |
| B-Cell Chronic
Lymphocytic Leukemia (B-CLL)/ Prolymphocytic Leukemia (B-PLL)/ Small Lymphocytic
Leukemia (B-SLL) |
+ |
+ |
+ |
- |
- |
+ |
- |
- |
CD10-; CD11c-/+ (ft); CD23+; CD43+;
sIgM ft; sIgD+/-; cIg-/+ |
Ig HC & LC
rg; +12 (33%); ab 13q
(¾25%); t(11;14) & bcl-1 rg
reported |
| Lymphoplasmacytoid
Lymphoma |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10-; CD11c ps (ft); CD25 ps (ft);
CD43+/-; sIg+; cIg+; (us M); IgD- (us) |
Ig HC & LC rg |
| Mantle Cell
Lymphoma |
+ |
+ |
+ |
- |
- |
+ |
- |
- |
CD10-/+; CD11c-; CD23-; CD43+;
sIgM+; IgD+ (us); lambda > kappa; disorganized FDC |
mj t(11;14)
w/Ig HC & bcl-1 |
| Follicle Center
Lymphoma, Follicular; Grades: I (Predominantly Small Cell); II (Mixed); III
(Predominantly Large Cell); Provisional Subtype: Diffuse (Predominantly Small
Cell) |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10+/-; CD11c-; CD23-/+; CD43-;
sIg+
(M+/-D > G > A); Bcl-2+ in follicles; organized FDC |
t(14;18) w/bcl-2
(70-95%) |
| Marginal Zone
B-Cell Lymphoma; 1)Extranodal: Low-grade B-cell lymphoma of MALT type (+/-
monocytoid B-cells); 2) Nodal: (+/- monocytoid B-cells) |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10-; CD11c+/-; CD23-; CD43-/+;
sIg+
(M >G or A); IgD-; cIg+ (40%) |
No bcl-1
or bcl-2 rg; +3 and/or
t(11;18) reported in extranodal type |
| Splenic Marginal
Zone Lymphoma, w/ or w/o Villous Lymphocytes (provisional entity) |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10-; CD11c+/-; CD23-; CD43-/+;
CD25-; sIg+ (M>G or A; lack IgD); cIg+ (40%); TRAP- |
Not well studied; +3 nd |
| Hairy Cell
Leukemia |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10-; CD11c+
(st); CD23-; CD25+ (st);
CD103+; sIg+ (M+/- D, G or A); FMC7+; TRAP+ (mj) |
Ig HC & LC rg |
| Plasmacytoma/Plasma
Cell myeloma |
- |
- |
- |
- |
- |
- |
- |
- |
CD30+; CD38+; CD43+/-; CD45-/+;
CD56+/-; sIg-; cIg+ (G, A, rare D/E; or LC only); HLADR/+; EMA-/+ |
Ig HC & LC rg or deleted |
| Diffuse Large
B-Cell Lymphoma |
+ |
+ |
+ |
- |
- |
-/+ |
- |
- |
CD10-/+; CD45+/-;
sIg+/-; cIg-/+ |
bcl-2 rg (30%);
c-myc rg (rp); bcl-6
rg; EBV+ in PTLD, HIV |
| Primary
Mediastinal (Thymic) Large B-Cell Lymphoma (Large B-Cell Lymphoma Subtype) |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD15-; CD30-/+; CD45+/-;
sIg- |
Ig HC & LC rg |
| Burkitt's
Lymphoma |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10+; CD23-;
sIgM+ |
t(8;14); t(2;8); or t(8;22) of c-myc |
| High-Grade
B-Cell Lymphoma, Burkitt-like (provisional entity) |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD10- (us);
sIg+/-; cIg ps |
bcl-2 rg (30%);
c-myc rg (un) |
| T Cell Lymphomas |
|
|
|
|
|
|
|
|
|
|
| Precursor T-Lymphoblastic
Lymphoma/Leukemia (T-LBL) |
- |
- |
- |
+/- |
+/- |
+/- |
+ |
CD4+/ CD8+ or CD4- / CD8- |
CD1a+/-; cytoplasmic CD3; CD16
oc;
CD57 oc; TdT+; Ig-; alpha-beta or gamma-delta or no TCRs |
TCR rg
(vr); Ig HC (ps) |
| T-Cell Chronic
Lymphocytic Leukemia (T-CLL)/T-Prolymphocytic Leukemia (T-PLL) |
- |
- |
- |
+ |
+ |
+ |
+ |
CD4+ / CD8-(65%);
CD4+/CD8+ (21%); CD4-/CD8+ rare |
CD25- |
clonal TCR
rg: inv14(q11; q32) in
75%; +8q |
| T-Cell Large
Granular Lymphocyte Leukemia (T-LGL) |
- |
- |
- |
+ |
+ |
- |
- |
CD4-/CD8+ |
CD16+; CD25-; CD56-/+; CD57+/-;
TCRalpha/betaR+ |
clonal TCR rg |
| NK-Cell Large
Granular Lymphocyte (LGL) Leukemia (NK-LGL) |
- |
- |
- |
+ |
- |
- |
- |
- |
CD16+; CD56+/-; CD57+/-;
TCRalpha/beta- |
TCR germ |
| Mycosis
Fungoides/ Sézary Syndrome |
- |
- |
- |
+ |
+ |
+ |
0.3 |
CD4+/CD8- |
CD25- (us) |
clonal TCR rg |
| Peripheral
T-Cell Lymphomas, Unspecified (Medium-, mixed Medium & Large-, Large-Cell) |
- |
ra |
- |
+/- |
+/- |
+/- |
-/+ |
CD4+ > CD8+;CD4-/CD8- ps |
CD45RA+ & CD45RO-
(ps) |
TCR rg (us); Ig genes germ |
| Angioimmunoblastic
T-Cell Lymphoma |
- |
- |
- |
+ |
+ |
+ |
+ |
CD4+ > CD8+ |
expanded FDC surrounding venules |
TCR rg (75%); Ig HC rg (10%); EBV
genome + (of); +3 and/or +5 (ps) |
| Angiocentric
Lymphoma |
- |
- |
- |
+ |
- (of) |
+/- |
+/- |
either + |
CD56+ (of) |
TCR & Ig germ; EBV genome + (us) |
| Intestinal
T-Cell Lymphoma (with or without Enteropathy) |
- |
- |
- |
+ |
+ |
+ |
+ |
CD4-/CD8+/- |
CD103+ |
clonal TCRbeta rg |
| Adult T-Cell
Lymphoma/Leukemia (ATL/L) |
- |
- |
- |
+ |
+ |
+ |
- |
CD4+ >> CD8+ |
CD25+ |
clonal TCR
rg; clonal integrated
HTLV-1 genome + |
| Anaplastic large
Cell (CD30+) Lymphoma (T- and Null-Cell Types) |
-/+ |
-/+ |
-/+ |
+/- |
-/+ |
vr |
vr |
vr |
CD15-/+; CD25+/-; CD30+; CD43-/+;
CD45+/-; CD45RO-/+; CD68-5 EMA+/- |
t(2;5); TCR rg (50-60%) |
| ALCL
Hodgkin's-Like /Hodgkin's-related (provisional entity) |
-/+ |
-/+ |
-/+ |
+/- |
-/+ |
vr |
vr |
vr |
CD15-/+; CD25+/-; CD30+; CD43-/+;
CD45+/-; CD45RO-/+; CD68-5; EMA+/-6; EBV- |
unknown |
| Hodgkin's
Disease (HD) |
|
|
|
|
|
|
|
|
|
|
| Lymphocyte
Predominance (Paragranuloma) HD |
+ |
+ |
+ |
- |
- |
- |
- |
- |
CD15-; CD30-/+; CD45+; CD57+ T-cells
surround L&H cells; EMA+/-; Ig- (us); prom FDC mesh |
Ig & TCR germ;
EBV- (mj) |
| Nodular
Sclerosis HD |
- |
- |
- |
- |
- |
- |
- |
- |
CD15+/-; CD30+; CD45-;
EMA- |
Ig & TCR germ (us);
EBV+ (40%) |
| Mixed
Cellularity HD |
- |
- |
- |
- |
- |
- |
- |
- |
CD15+/-; CD30+; CD45-;
EMA- |
Ig & TCR germ (us);
EBV+
(60-70%) |
| Lymphocyte
Depletion HD |
- |
- |
- |
- |
- |
- |
- |
- |
CD15+/-; CD30+; CD45-;
EMA- |
Ig & TCR germ |
| Lymphocyte-Rich
Classical HD (provisional entity) |
Similar to Nodular
Sclerosis and Mixed Cellularity HD |